These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 37338479)

  • 1. Safety of antituberculosis agents used for multidrug-resistant tuberculosis among patients attending the Jamot Hospital of Yaounde, Cameroon.
    Mpoh MM; Deli V; Daniel TT; Salvo F
    Int J Mycobacteriol; 2023; 12(2):168-174. PubMed ID: 37338479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Kanamycin-induced ototoxicity during treatment of multidrug-resistant tuberculosis].
    Poka-Mayap V; Balkissou Adamou D; Pefura-Yone EW; Kuaban C
    Rev Mal Respir; 2020 May; 37(5):369-375. PubMed ID: 32278508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence and factors associated with unfavourable treatment outcome among patients with rifampicin-resistant pulmonary tuberculosis in Yaoundé, Cameroon.
    Kuaban A; Balkissou AD; Ekongolo MCE; Nsounfon AW; Pefura-Yone EW; Kuaban C
    Pan Afr Med J; 2021; 38():229. PubMed ID: 34046134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
    Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statistical factors associated with utilisation of ototoxicity monitoring services for multi-drug-resistant tuberculosis patients in the Western Cape.
    Ramma L; Nhokwara PT; Rogers C
    S Afr J Commun Disord; 2019 Jan; 66(1):e1-e6. PubMed ID: 30843411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse outcome pathway for aminoglycoside ototoxicity in drug-resistant tuberculosis treatment.
    Hong H; Dooley KE; Starbird LE; Francis HW; Farley JE
    Arch Toxicol; 2019 May; 93(5):1385-1399. PubMed ID: 30963202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV seroprevalence rate and incidence of adverse skin reactions in adults with pulmonary tuberculosis receiving thiacetazone free anti-tuberculosis treatment in Yaounde, Cameroon.
    Kuaban C; Bercion R; Koulla-Shiro S
    East Afr Med J; 1997 Aug; 74(8):474-7. PubMed ID: 9487410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Active surveillance for adverse events in patients on longer treatment regimens for multidrug-resistant tuberculosis in Viet Nam.
    Ngoc NB; Vu Dinh H; Thuy NT; Quang DV; Huyen CTT; Hoa NM; Anh NH; Dat PT; Hoa NB; Tiemersma E; Nhung NV
    PLoS One; 2021; 16(9):e0255357. PubMed ID: 34492031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acquired anti-tuberculosis drug resistance in Yaounde, Cameroon.
    Kuaban C; Bercion R; Jifon G; Cunin P; Blackett KN
    Int J Tuberc Lung Dis; 2000 May; 4(5):427-32. PubMed ID: 10815736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in VigiBase® reporting of aminoglycoside and capreomycin-suspected ototoxicity during tuberculosis treatment.
    Sagwa EL; Souverein PC; Ribeiro I; Leufkens HG; Mantel-Teeuwisse AK
    Pharmacoepidemiol Drug Saf; 2017 Jan; 26(1):1-8. PubMed ID: 27868278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic accuracy and usefulness of the Genotype MTBDRplus assay in diagnosing multidrug-resistant tuberculosis in Cameroon? a cross-sectional study.
    Abanda NN; Djieugoué JY; Lim E; Pefura-Yone EW; Mbacham WF; Vernet G; Penlap VM; Eyangoh SI; Taylor DW; Leke RGF
    BMC Infect Dis; 2017 May; 17(1):379. PubMed ID: 28569148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rates and risk factors for nephrotoxicity and ototoxicity among tuberculosis patients in Tbilisi, Georgia.
    Buziashvili M; Mirtskhulava V; Kipiani M; Blumberg HM; Baliashvili D; Magee MJ; Furin JJ; Tukvadze N; Kempker RR
    Int J Tuberc Lung Dis; 2019 Sep; 23(9):1005-1011. PubMed ID: 31615608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Second-line injectable induced ototoxicity in drug resistant tuberculosis: A systematic review of Indian studies.
    Sarin R; Behera D; Khanna A; Singh V; Narang P; Deepak TS
    Indian J Tuberc; 2019 Apr; 66(2):279-287. PubMed ID: 31151497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bedaquiline safety, efficacy, utilization and emergence of resistance following treatment of multidrug-resistant tuberculosis patients in South Africa: a retrospective cohort analysis.
    Pai H; Ndjeka N; Mbuagbaw L; Kaniga K; Birmingham E; Mao G; Alquier L; Davis K; Bodard A; Williams A; Van Tongel M; Thoret-Bauchet F; Omar SV; Bakare N
    BMC Infect Dis; 2022 Nov; 22(1):870. PubMed ID: 36414938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Occurrence, Management, and Risk Factors for Adverse Drug Reactions in Multidrug Resistant Tuberculosis Patients.
    Ahmad N; Javaid A; Syed Sulaiman SA; Afridi AK; Zainab ; Khan AH
    Am J Ther; 2018; 25(5):e533-e540. PubMed ID: 26938643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nephrotoxicity and ototoxic symptoms of injectable second-line anti-tubercular drugs among patients treated for MDR-TB in Ethiopia: a retrospective cohort study.
    Shibeshi W; Sheth AN; Admasu A; Berha AB; Negash Z; Yimer G
    BMC Pharmacol Toxicol; 2019 May; 20(1):31. PubMed ID: 31122273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon.
    Kuaban C; Noeske J; Rieder HL; Aït-Khaled N; Abena Foe JL; Trébucq A
    Int J Tuberc Lung Dis; 2015 May; 19(5):517-24. PubMed ID: 25868018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early results of systematic drug susceptibility testing in pulmonary tuberculosis retreatment cases in Cameroon.
    Noeske J; Voelz N; Fon E; Abena Foe JL
    BMC Res Notes; 2012 Mar; 5():160. PubMed ID: 22436423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bedaquiline-containing regimens in patients with pulmonary multidrug-resistant tuberculosis in China: focus on the safety.
    Gao JT; Du J; Wu GH; Pei Y; Gao MQ; Martinez L; Fan L; Chen W; Xie L; Chen Y; Wang H; Jin L; Li GB; Zong PL; Xiong Y; Wu QH; Li MW; Yan XF; Miao YF; Cai QS; Li XJ; Bai DP; Geng SJ; Yang GL; Tang PJ; Zeng Y; Chen XH; Li TX; Cai C; Zhou Y; Zhuo M; Wang JY; Guan WL; Xu L; Shi JC; Shu W; Cheng LL; Teng F; Ning YJ; Xie SH; Sun YX; Zhang LJ; Liu YH
    Infect Dis Poverty; 2021 Mar; 10(1):32. PubMed ID: 33736710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.